Article

Analysis: Drug Costs Become Bigger Issue in Cancer Care

In the past, money was no object when cancer specialists considered which drugs would provide the best treatment for their patients.

But some top oncologists are rethinking that stance, given the soaring costs of new cancer medicines, reduced reimbursement by insurance plans and fresh research that has identified cases where cheaper generic drugs can work just as well - or better - than expensive brand-name medications.

Read the full story:

http://tinyurl.com/d2ltzp2

Source: Reuters

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo